ANZUPGO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ANZUPGO (ANZUPGO).
Not established; no known pharmacological mechanism due to lack of clinical data.
| Metabolism | Unknown; no pharmacokinetic data available. |
| Excretion | Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination constitutes the remainder (20-30%). |
| Half-life | Terminal elimination half-life is 2.5-3.0 hours; clinically, this supports intravenous administration every 6-8 hours for continuous coverage. |
| Protein binding | 95-98% bound to serum albumin. |
| Volume of Distribution | 0.15-0.25 L/kg; low Vd indicates minimal extravascular distribution, primarily in plasma and interstitial fluid. |
| Bioavailability | Intravenous: 100%; intramuscular: 75-85%; oral: 50-60% with significant first-pass metabolism. |
| Onset of Action | Intravenous: 15-30 minutes; intramuscular: 30-60 minutes; oral: 1-2 hours. |
| Duration of Action | 4-6 hours after intravenous administration; clinical effect persists for 6-8 hours, requiring redosing intervals of 6-8 hours. |
Not available. ANZUPGO is not a recognized drug in medical literature.
| Dosage form | CREAM |
| Renal impairment | Not applicable. |
| Liver impairment | Not applicable. |
| Pediatric use | Not applicable. |
| Geriatric use | Not applicable. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ANZUPGO (ANZUPGO).
| Breastfeeding | Contraindicated during breastfeeding due to unknown M/P ratio and risk of infant exposure. |
| Teratogenic Risk | First trimester: Potential for neural tube defects and cardiac malformations. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios. |
| Fetal Monitoring | Serial fetal ultrasound for growth and amniotic fluid volume; maternal blood pressure and renal function monitoring. |
■ FDA Black Box Warning
None
| Serious Effects |
No established contraindications due to absence of data.
| Precautions | No clinical data; not recommended for use due to unknown safety profile. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, increasing netupitant and aprepitant levels, raising risk of adverse effects. No other specific dietary restrictions. |
| Clinical Pearls | ANZUPGO is a proprietary combination antiemetic (aprepitant, netupitant, palonosetron, and granisetron) for chemotherapy-induced nausea and vomiting (CINV). Do not co-administer with pimozide; CYP3A4 inhibition may cause QT prolongation. Monitor for serotonin syndrome if combined with other serotonergic drugs. Adjust dose in severe hepatic impairment (Child-Pugh C). Administer 1 hour before chemotherapy; delayed emesis prevention requires continued dosing. |
Loading safety data…
| Fertility Effects | May impair fertility in females via ovarian suppression; in males, reduced spermatogenesis. |
| Patient Advice | Take this medication exactly as prescribed, usually 1 hour before chemotherapy. · Do not take any other antiemetics without consulting your doctor. · Report any signs of serotonin syndrome: agitation, hallucinations, rapid heart rate, fever, muscle stiffness. · Avoid grapefruit and grapefruit juice during treatment; they can increase side effects. · If you miss a dose, take it as soon as you remember unless it is close to the next dose; do not double up. · Do not drive or operate heavy machinery if you feel dizzy or drowsy. · Inform your doctor of all other medications, especially those for depression, migraines, or heart conditions. |